Advances in basic life science during the past decade have exponentially increased our understanding of the molecular bases of lung cancers and this improved insight has had great effects on diagnosis, prognosis, classification, and treatment of cancer. Similar to colorectal carcinoma, stepwise development of lung cancer has been proposed. For squamous neoplasm, dysplasia is considered to progress to invasive cancer through carcinoma in-situ in association with accumulations of genetic and epigenetic alterations. In lung adenocarcinoma, a preinvasive lesion, termed atypical adenomatous hyperplasia, progresses to an adenocarcinoma in situ, namely a bronchioloalveolar carcinoma, followed by an invasive adenocarcinoma. Currently, molecular alterations, which are involved in each transition, have been also revealed. In this review, I would like to discuss correlation of morphological features with the progression of lung adenocarcinoma with special reference to the most advanced component within the tumor. (J Lung Cancer 2010;9(2):53 56)
vague consensus concerning which atypia should be considered more significant according to the tumor type, there are two basic notions. One is that the grade of the tumor should be determined by the most prevalent grade, while the other is that the tumor grade should be determined by the highest grade in the tumor. In the case of lung adenocarcinoma mixed with components of small cell lung cancer (SCLC), the tumor grade is determined as grade 4 regardless of the extent of the SCLC component (1) . Indeed, combined SCLC/adenocarcinoma tumors frequently have metastases consisting solely of SCLC components. Because the component that is most advanced along the progression schema has the greatest chance of metastasis and/or clinical aggressiveness, we must decide how we should identify the most advanced component within a tumor morphologically. In general, it is accepted that a poorly differentiated portion of the tumor or the portion with the highest grade is the component that is the most advanced. In endometrial cancer, the histological grade is determined by the extent of the solid growth pattern, and a grade 3 tumor is defined as an endometrial carcinoma with 50% or more solid growth (2).
However, when notable nuclear atypia is seen, the tumor is evaluated as grade 3 regardless of the proportion of solid growth. Thus, endometrial carcinoma is graded primarily based on structural atypia, although cellular atypia are partly taken into consideration. In breast cancer, the Nottingham histological grading system is widely used (3, 4) , and this system is based on three features of the tumor cells: tubular formation, nuclear atypia and mitotic count. This system regards the structural and cellular atypia as equally significant. In lung cancer, the 2004 WHO classification does not define tumor differentiation or grade because of the lack of reproducibility and clinical significance (1). However, the solid growth component is of a higher grade than the papillary component, according to the general consensus of tumor grading. Therefore, the tumor portion with a solid growth pattern (Fig. 1A) appears to be more advanced along the cancer progression schema than the component with papillary growth (Fig. 1B) .
On the other hand, there is a paradigm in modern molecular oncology that cancer progresses in a multi-step fashion. it has been shown that a copy number gain of the fusion gene is present in the high-grade lesion, in addition to the translocation (6).
We recently proposed a hypothesis concerning genetic alterations of epidermal growth factor receptor (EGFR) (7).
Within a tumor, EGFR is mutated uniformly, while EGFR amplification is heterogeneously distributed. Detailed examination revealed that EGFR amplification was detected exclusively in invasive and/or high-grade areas. In addition, when the frequencies of the EGFR amplification according to the progression steps from precancerous lesion to invasive cancer were compared, EGFR was disproportionally amplified among the progression steps, although EGFR mutation rates showed almost equal frequencies. These findings suggested that the EGFR mutation is involved in the very early steps of progression, whereas EGFR amplification is acquired in association with tumor progression. These findings have been confirmed by others (8, 9) . Therefore, a proportion of a tumor exhibiting EGFR amplification could be regarded as indicative of a lesion that is more advanced. Accordingly, EGFR mutations and amplification were examined in each of the tumor portions shown in Fig. 1A and B. The cribriform/solid component (Fig. 1A) harbored an EGFR mutation but not EGFR amplification. In contrast, both EGFR mutation and amplification were detected in the acinar component, which had a higher level of nuclear atypia (Fig.   1B ). This result suggests that the acinar component is more advanced than the cribriform/solid component. We further examined various morphological components and found that morphological changes generally corresponded to EGFR amplification; however, there were differences in the EGFR amplification even among morphologically identical components. Fig. 1C and D are examples of such tissues.
Similarly, Fig. 2 shows a lung adenocarcinoma that harbors a resistance mutation after EGFR-tyrosine kinase inhibitor treatment. This patient, who had cT2N0M0 lung adenocarcinoma, was treated with gefitinib because treatment with cytotoxic drugs was refused. This treatment was very effective, especially in the mediastinal lymph nodes, but two months later, the primary tumor began to regrow. Surgical resection and lymph node dissection were completed. The hot spot point mutation L858R was detected in both the primary nodule and in the metastatic tumor in the lymph node, but a resistance mutation, T790M, was superimposed only in the regrown primary tumor. According to the progression schema, the primary tumor with the secondary T790M mutation is likely to be the portion that is more advanced (10) . Are the morphological features in Fig. 2 consistent with this genetic difference?
The results appear to suggest that morphological features are not always associated with genetic differences. However, I do not consider this conclusion to be the result of the inferior capability of pathologists; it is simply the result of using inadequate morphological indicators. If adequate indicators were obtained, our pathologists could integrate morphologybased wisdom with molecular biology-based knowledge that directly connects to clinical treatment.
